Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gmachl

Showing results (91-100 of 96) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 96 results.
Biorxiv : the Preprint Server for Biology|February 7, 2023
Combined KRAS<sup>G12C</sup> and SOS1 inhibition enhances and extends the anti-tumor response in KRAS<sup>G12C</sup>-driven cancers by addressing intrinsic and acquired resistanceVenu Thatikonda, Hengyu Lu, Sabine Jurado, et al.
Journal of Medicinal Chemistry|March 15, 2021
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRASJuergen Ramharter, Dirk Kessler, Peter Ettmayer, et al.
Cancer Discovery|August 21, 2020
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK InhibitionMarco H Hofmann, Michael Gmachl, Juergen Ramharter, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2019
Drugging an undruggable pocket on KRASDirk Kessler, Michael Gmachl, Andreas Mantoulidis, et al.
Nature Cancer|August 5, 2024
Co-targeting SOS1 enhances the antitumor effects of KRAS<sup>G12C</sup> inhibitors by addressing intrinsic and acquired resistanceVenu Thatikonda, Hengyu Lyu, Sabine Jurado, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2020
Reply to Tran et al.: Dimeric KRAS protein-protein interaction stabilizersDirk Kessler, Andreas Gollner, Michael Gmachl, et al.
Pageof 10

Showing results (91-100 of 96) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 96 results.
Biorxiv : the Preprint Server for Biology|February 7, 2023
Combined KRAS<sup>G12C</sup> and SOS1 inhibition enhances and extends the anti-tumor response in KRAS<sup>G12C</sup>-driven cancers by addressing intrinsic and acquired resistanceVenu Thatikonda, Hengyu Lu, Sabine Jurado, et al.
Journal of Medicinal Chemistry|March 15, 2021
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRASJuergen Ramharter, Dirk Kessler, Peter Ettmayer, et al.
Cancer Discovery|August 21, 2020
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK InhibitionMarco H Hofmann, Michael Gmachl, Juergen Ramharter, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2019
Drugging an undruggable pocket on KRASDirk Kessler, Michael Gmachl, Andreas Mantoulidis, et al.
Nature Cancer|August 5, 2024
Co-targeting SOS1 enhances the antitumor effects of KRAS<sup>G12C</sup> inhibitors by addressing intrinsic and acquired resistanceVenu Thatikonda, Hengyu Lyu, Sabine Jurado, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2020
Reply to Tran et al.: Dimeric KRAS protein-protein interaction stabilizersDirk Kessler, Andreas Gollner, Michael Gmachl, et al.
Pageof 10